Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,161 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02984423 | FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study(FLABRA) | completed | — | 471 | AstraZenecaINDUSTRY | 6 | Jul 10, 2020 | clinicaltrials |
| NCT01250223 | Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) | completed | — | 1,093 | Associazione Angela Serra per la ricerca sul cancroOTHER |
| 8 |
| Jul 9, 2020 |
| clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 1,276 | Eisai Inc.INDUSTRY | 23 | Jun 18, 2020 | clinicaltrials |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | completed | Phase 3 | 1,289 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 18, 2020 | clinicaltrials |
| NCT00967616 | Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy | completed | Phase 2 | 100 | Daiichi SankyoINDUSTRY | 5 | May 4, 2020 | clinicaltrials |
| NCT03059251 | Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina | completed | — | 2 | Hoffmann-La RocheINDUSTRY | 1 | Apr 17, 2020 | clinicaltrials |
| NCT00026338 | Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer | completed | Phase 3 | 569 | NCIC Clinical Trials GroupNETWORK | 19 | Apr 2, 2020 | clinicaltrials |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy(A+B) | terminated | Phase 3 | 346 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 27, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT04293315 | Screening of Colorectal Cancer in the Public Healthcare Sector in Argentina | unknown | N/A | 1,520 | Institute for Clinical Effectiveness and Health PolicyOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03338777 | Suicide Plus Immune Gene Therapy for Advanced Melanoma(IGTM-101) | terminated | Early Phase 1 | 4 | Hospital Italiano de Buenos AiresOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | completed | Phase 3 | 117 | Alexion Pharmaceuticals, Inc.INDUSTRY | 17 | Feb 5, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT00388726 | E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 3 | 762 | Eisai Inc.INDUSTRY | 17 | Jan 7, 2020 | clinicaltrials |
| NCT02008227 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy(OAK) | completed | Phase 3 | 1,225 | Hoffmann-La RocheINDUSTRY | 31 | Dec 20, 2019 | clinicaltrials |
| NCT02066961 | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer(ASPIRE-PCa) | completed | — | 1,533 | Astellas Pharma Global Development, Inc.INDUSTRY | 27 | Dec 20, 2019 | clinicaltrials |
| NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | completed | Phase 2 | 30 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
| NCT02354508 | Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues | completed | Phase 3 | 123 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 10, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT00505414 | A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine | terminated | Phase 3 | 136 | Grünenthal GmbHINDUSTRY | 6 | Nov 1, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00825955 | Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment(BRISK PS) | completed | Phase 3 | 587 | Bristol-Myers SquibbINDUSTRY | 19 | Oct 9, 2019 | clinicaltrials |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)(PIPACRegis) | unknown | — | 1,000 | Sabine RhodeOTHER | 13 | Oct 8, 2019 | clinicaltrials |
| NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | completed | Phase 3 | 272 | mAbxience Research S.L.INDUSTRY | 12 | Sep 26, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01168973 | A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | completed | Phase 3 | 1,253 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 25, 2019 | clinicaltrials |
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | completed | Phase 3 | 1,072 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 25, 2019 | clinicaltrials |
| NCT01419717 | Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer | completed | Phase 3 | 129 | AmgenINDUSTRY | 19 | Sep 24, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT00490451 | A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 18, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT01721044 | A Moderate to Severe Rheumatoid Arthritis Study(RA-BEACON) | completed | Phase 3 | 527 | Eli Lilly and CompanyINDUSTRY | 22 | Sep 18, 2019 | clinicaltrials |
| NCT01091168 | Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer | completed | Phase 3 | 594 | Pierre Fabre MedicamentINDUSTRY | 14 | Sep 16, 2019 | clinicaltrials |
| NCT00087711 | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 3 | 1,713 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 12, 2019 | clinicaltrials |
| NCT03988114 | A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer(proMONARCH) | withdrawn | Phase 4 | 0 | Eli Lilly and CompanyINDUSTRY | 9 | Sep 6, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT02164292 | ALPPS: Safety, Feasibility and Efficacy at a Single Center | completed | — | 30 | Hospital Italiano de Buenos AiresOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02765503 | Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial(HYPNO) | unknown | N/A | 836 | International Atomic Energy AgencyOTHER_GOV | 9 | Aug 8, 2019 | clinicaltrials |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | completed | Phase 3 | 831 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 31, 2019 | clinicaltrials |
| NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy(PROLONG) | terminated | Phase 3 | 480 | Novartis PharmaceuticalsINDUSTRY | 25 | Jul 30, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials